KBC Group’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$51K Hold
4,746
– – ﹤0.01% 1717
2026
Q2
$45K Hold
4,746
– – ﹤0.01% 1736
2026
Q1
$39K Buy
4,746
+1,229
+35% +$11.1K ﹤0.01% 1730
2025
Q4
$24K Hold
3,517
– – ﹤0.01% 1723
2025
Q3
$30K Hold
3,517
– – ﹤0.01% 1721
2025
Q2
$22K Sell
3,517
-4,437
-56% -$29.4K ﹤0.01% 1705
2025
Q1
$51K Hold
7,954
– – ﹤0.01% 1786
2024
Q4
$64K Buy
7,954
+3,917
+97% +$37.8K ﹤0.01% 1766
2024
Q3
$51K Hold
4,037
– – ﹤0.01% 1701
2024
Q2
$51K Buy
+4,037
New +$40.6K ﹤0.01% 1601
2023
Q4
– Sell
-1,798
Closed -$13K – 1897
2023
Q3
$13K Buy
+1,798
New +$14.4K ﹤0.01% 1910
2022
Q4
– Sell
-736
Closed -$13K – 1544
2022
Q3
$13K Hold
736
– – ﹤0.01% 1539
2022
Q2
$38K Sell
736
-2,520
-77% -$131K ﹤0.01% 1467
2022
Q1
$240K Hold
3,256
– – ﹤0.01% 998
2021
Q4
$466K Sell
3,256
-2,436
-43% -$419K ﹤0.01% 890
2021
Q3
$1.18M Hold
5,692
– – ﹤0.01% 738
2021
Q2
$1.21M Buy
+5,692
New +$1.04M ﹤0.01% 741

Other funds holding NVAX

KBC Group's NVAX Position: Q3 2026 in Review

KBC Group held its Novavax (NVAX) position steady in Q3 2026 at 4,746 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

KBC Group first reported a position in NVAX in Q2 2021 and has held it in 17 quarters since. The position peaked at $1.21M in Q2 2021. 203 funds tracked by Wall St. Rank hold NVAX as of Q3 2026.

  • KBC Group held 4,746 shares of Novavax worth $51K as of Q3 2026.
  • KBC Group left its Novavax share count unchanged in Q3 2026.
  • Novavax made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1717 holding.
  • KBC Group first reported a position in Novavax in Q2 2021 and has held it in 17 quarters since.
  • KBC Group's Novavax position peaked at $1.21M in Q2 2021.
  • 203 funds tracked by Wall St. Rank held Novavax as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.